Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

por Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Nagai, Hiroki, Takatani, Masahiro, Yasui, Hisateru
Publicado 2023

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

por Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Nagai, Hiroki, Takatani, Masahiro, Yasui, Hisateru
Publicado 2023

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

por Matsumoto, Toshihiko, Yamamura, Shogo, Ikoma, Tatsuki, Kurioka, Yusuke, Doi, Keitaro, Boku, Shogen, Shibata, Nobuhiro, Nagai, Hiroki, Shimada, Takanobu, Tsuduki, Takao, Tsumura, Takehiko, Takatani, Masahiro, Yasui, Hisateru, Satake, Hironaga
Publicado 2022

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

por Matsumoto, Toshihiko, Yamamura, Shogo, Ikoma, Tatsuki, Kurioka, Yusuke, Doi, Keitaro, Yasuda, Tomoyo, Boku, Shogen, Kawai, Takashi, Shibata, Nobuhiro, Nagai, Hiroki, Tsuduki, Takao, Shimada, Takanobu, Matsumoto, Yusuke, Tsumura, Takehiko, Takatani, Masahiro, Yasui, Hisateru, Satake, Hironaga
Publicado 2022